EPH106 Comparison of the Post-Marketing Safety Profile between Influenza and COVID-19 Vaccines: An Analysis of the Vaccine Adverse Event Reporting System (VAERS)

Detalles Bibliográficos
Autores principales: Alahmari, AK, Almalki, Z, Alshehri, A, Albassam, AA, Ahmed, NJ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232798/
http://dx.doi.org/10.1016/j.jval.2022.04.857
_version_ 1784735675757625344
author Alahmari, AK
Almalki, Z
Alshehri, A
Albassam, AA
Ahmed, NJ
author_facet Alahmari, AK
Almalki, Z
Alshehri, A
Albassam, AA
Ahmed, NJ
author_sort Alahmari, AK
collection PubMed
description
format Online
Article
Text
id pubmed-9232798
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-92327982022-06-27 EPH106 Comparison of the Post-Marketing Safety Profile between Influenza and COVID-19 Vaccines: An Analysis of the Vaccine Adverse Event Reporting System (VAERS) Alahmari, AK Almalki, Z Alshehri, A Albassam, AA Ahmed, NJ Value Health Article Published by Elsevier Inc. 2022-07 2022-06-25 /pmc/articles/PMC9232798/ http://dx.doi.org/10.1016/j.jval.2022.04.857 Text en Copyright © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Alahmari, AK
Almalki, Z
Alshehri, A
Albassam, AA
Ahmed, NJ
EPH106 Comparison of the Post-Marketing Safety Profile between Influenza and COVID-19 Vaccines: An Analysis of the Vaccine Adverse Event Reporting System (VAERS)
title EPH106 Comparison of the Post-Marketing Safety Profile between Influenza and COVID-19 Vaccines: An Analysis of the Vaccine Adverse Event Reporting System (VAERS)
title_full EPH106 Comparison of the Post-Marketing Safety Profile between Influenza and COVID-19 Vaccines: An Analysis of the Vaccine Adverse Event Reporting System (VAERS)
title_fullStr EPH106 Comparison of the Post-Marketing Safety Profile between Influenza and COVID-19 Vaccines: An Analysis of the Vaccine Adverse Event Reporting System (VAERS)
title_full_unstemmed EPH106 Comparison of the Post-Marketing Safety Profile between Influenza and COVID-19 Vaccines: An Analysis of the Vaccine Adverse Event Reporting System (VAERS)
title_short EPH106 Comparison of the Post-Marketing Safety Profile between Influenza and COVID-19 Vaccines: An Analysis of the Vaccine Adverse Event Reporting System (VAERS)
title_sort eph106 comparison of the post-marketing safety profile between influenza and covid-19 vaccines: an analysis of the vaccine adverse event reporting system (vaers)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232798/
http://dx.doi.org/10.1016/j.jval.2022.04.857
work_keys_str_mv AT alahmariak eph106comparisonofthepostmarketingsafetyprofilebetweeninfluenzaandcovid19vaccinesananalysisofthevaccineadverseeventreportingsystemvaers
AT almalkiz eph106comparisonofthepostmarketingsafetyprofilebetweeninfluenzaandcovid19vaccinesananalysisofthevaccineadverseeventreportingsystemvaers
AT alshehria eph106comparisonofthepostmarketingsafetyprofilebetweeninfluenzaandcovid19vaccinesananalysisofthevaccineadverseeventreportingsystemvaers
AT albassamaa eph106comparisonofthepostmarketingsafetyprofilebetweeninfluenzaandcovid19vaccinesananalysisofthevaccineadverseeventreportingsystemvaers
AT ahmednj eph106comparisonofthepostmarketingsafetyprofilebetweeninfluenzaandcovid19vaccinesananalysisofthevaccineadverseeventreportingsystemvaers

Ejemplares similares